Advances in the Diagnosis and Management of Lung Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 833

Special Issue Editors


E-Mail Website
Guest Editor
Division of Pulmonary, Critical Care and Sleep Medicine, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Interests: research updates in pleural effusions
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Loma Linda University Medical Center, Loma Linda, CA, USA
Interests: lung cancer

E-Mail Website
Guest Editor
Division of Pulmonary and Critical Care Medicine, Section of Thoracic Surgery, Department of Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
Interests: lung disease

Special Issue Information

Dear Colleagues,

The Special Issue "Advances in the Diagnosis and Management of Lung Cancer" focuses intently on the latest scientific advancements in diagnosing lung cancer. This comprehensive collection explores the sophisticated imaging modalities, biomarker screenings, and other diagnostic techniques that are revolutionizing our ability to detect lung cancer at its earliest stages. The articles in this Special Issue delve into the latest advancements in radiological imaging, including high-resolution computed tomography and positron emission tomography, which are enabling more precise and accurate lung cancer detection. Additionally, this Special Issue highlights the role of genetic testing and biomarker analysis in lung cancer diagnosis, providing insights into the potential of personalized medicine in this field. This collection offers a valuable overview of the latest trends and developments in lung cancer diagnosis, enabling healthcare professionals to stay updated with the latest practices and improve early detection rates, ultimately leading to better patient outcomes.

Dr. George Z. Cheng
Dr. Ara Chrissian
Dr. Jose De Cardenas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomic-based diagnostic markers
  • imaging techniques for lung cancer detection
  • liquid biopsy in lung cancer diagnostics
  • artificial intelligence in lung cancer screening
  • early detection biomarkers
  • molecular profiling for lung cancer diagnosis
  • endoscopic advances in lung cancer diagnosis
  • precision diagnostics in lung cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 4615 KiB  
Case Report
RT-PCR Misdiagnosis of Patient with Rare EGFR Mutation Lung Adenocarcinoma: Is NGS the Only Solution?
by Piotr Piekarczyk, Urszula Lechowicz, Janusz Szopiński, Mateusz Polaczek, Katarzyna Błasińska and Katarzyna Modrzewska
Diagnostics 2025, 15(7), 842; https://doi.org/10.3390/diagnostics15070842 - 25 Mar 2025
Viewed by 368
Abstract
Background and Clinical Significance: Molecular testing plays a crucial role in lung cancer diagnosis and management. While single-gene tests (SGTs) remain an important diagnostic tool, developments in novel methods such as next generation sequencing (NGS) provide a more precise mutational profile and enable [...] Read more.
Background and Clinical Significance: Molecular testing plays a crucial role in lung cancer diagnosis and management. While single-gene tests (SGTs) remain an important diagnostic tool, developments in novel methods such as next generation sequencing (NGS) provide a more precise mutational profile and enable the targeted treatment of a larger scope of mutation-driven cancers. Case presentation: We present a case of a patient with a rare EGFR variant lung adenocarcinoma, who was misdiagnosed using a SGT. The initial treatment with immunotherapy was unsuccessful. Conclusions: The patient could have benefited if NGS had been performed instead of traditional real-time polymerase chain reaction (RT-PCR) and if adequate tyrosine kinase inhibitor treatment was initiated at the time of diagnosis. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Management of Lung Cancer)
Show Figures

Figure 1

Back to TopTop